Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

NASAC Statement On The Occasion Of The G8+5 Summit In L'Aquila, Italy
A group of scientific academies in Africa encourages the G8+5 countries to help Africa stem the scientific brain drain.
generic viagra online
St. Petersburg Times Examines Work Of Paul Farmer, Potential Candidate For USAID, State Department Position
The St. Petersburg Times examines the work of Paul Farmer - "the Harvard-educated doctor who, starting in Haiti, built a multinational organization on the radical idea that poor patients deserve the same care as rich ones" and is reportedly being considered for a high-level job with USAID or the State Department. The newspaper reports that though it"s "not a sure thing, even his candidacy indicates how far the international aid establishment has come around to Farmer"s way of thinking, health care experts say."
News of the day
Low Prevalence Of HPV Infection May Be Tied To Poor Prognosis For Blacks With Head And Neck Cancer
Researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer have found that head and neck cancer patients who test positive for the human papillomavirus (HPV) have much better survival rates than patients who don"t have the virus, according to a new study in the journal Cancer Prevention Research. The researchers also discovered that blacks in the study had a very low rate of HPV infection, and consequently worse survival, which may explain why African-American patients traditionally have had a poor prognosis for head and neck cancer.
Health Insurance

Genetically-Engineered MSCs Kill Metastatic Lung Cancer Cells In Mice

Researchers in London have demonstrated the ability of adult stem cells from bone marrow (mesenchymal stem cells, or MSCs) to deliver a cancer-killing protein to tumors. The genetically engineered stem cells are able to home to the cancer cells, both in culture and in mouse models, and deliver TNF-related apoptosis-inducing ligand (TRAIL), destroying the tumor cells while sparing normal cells. The research will be presented on Tuesday, May 19, at the American Thoracic Society"s 105th International Conference in San Diego. "Present oncological therapies are limited by host toxicity," said Michael Loebinger, M.D., M.A, who, along with S. M. Janes, M.D., Ph.D., conducted the research at the Centre for Respiratory Research at the University College of London. "They are also limited by cancer resistance and may not destroy cancer stem cells." With these experiments, the investigators combined two disparate areas of research that they believed held promise for treating cancer. Studies had shown that MSCs can be used as vectors to deliver anti-tumor therapy, while other studies found that TRAIL killed cancer cells, but not normal cells. For their experiments, Drs. Loebinger and Janes identified those cells likely to be resistant to therapies (cancer cells that have characteristics of stem cells) and found that they were just as likely to be destroyed as tumor cells by this novel therapy. In culture, the stem cells caused lung, squamous, breast and cervical cancer cells to die (all p


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009